

World Journal of *Hepatology*

World J Hepatol 2023 February 27; 15(2): 123-320



EDITORIAL

- 123 Metabolic-associated fatty liver disease: New nomenclature and approach with hot debate
Fouad Y

REVIEW

- 129 Current status and prospect of treatments for recurrent hepatocellular carcinoma
Yang YQ, Wen ZY, Liu XY, Ma ZH, Liu YE, Cao XY, Hou L, Hui X
- 151 Bioengineering liver tissue by repopulation of decellularised scaffolds
Afzal Z, Huguet EL
- 180 Antioxidant and anti-inflammatory agents in chronic liver diseases: Molecular mechanisms and therapy
Zhang CY, Liu S, Yang M

MINIREVIEWS

- 201 Galectin-3 inhibition as a potential therapeutic target in non-alcoholic steatohepatitis liver fibrosis
Kram M
- 208 *Clostridioides difficile* infection in patients with nonalcoholic fatty liver disease-current status
Kiseleva YV, Maslennikov RV, Gadziakhmedova AN, Zharikova TS, Kalinin DV, Zharikov YO
- 216 Sonographic gallbladder wall thickness measurement and the prediction of esophageal varices among cirrhotics
Emara MH, Zaghoul M, Amer IF, Mahros AM, Ahmed MH, Elkerdawy MA, Elshenawy E, Rasheda AMA, Zaher TI, Haseeb MT, Emara EH, Elbatae H

ORIGINAL ARTICLE**Clinical and Translational Research**

- 225 Progressive changes in platelet counts and Fib-4 scores precede the diagnosis of advanced fibrosis in NASH patients
Zijlstra MK, Gampa A, Joseph N, Sonnenberg A, Fimmel CJ

Retrospective Cohort Study

- 237 Baseline hepatocyte ballooning is a risk factor for adverse events in patients with chronic hepatitis B complicated with nonalcoholic fatty liver disease
Tan YW, Wang JM, Zhou XB
- 255 Extended criteria brain-dead organ donors: Prevalence and impact on the utilisation of livers for transplantation in Brazil
Braga VS, Boteon APCS, Paglione HB, Pecora RAA, Boteon YL

- 265 Prevalence of non-alcoholic fatty liver disease in patients with nephrotic syndrome: A population-based study

Onwuzo SS, Hitawala AA, Boustany A, Kumar P, Almomani A, Onwuzo C, Monteiro JM, Asaad I

Retrospective Study

- 274 Diabetes mellitus is not associated with worse short term outcome in patients older than 65 years old post-liver transplantation

Alghamdi S, Alamro S, Alobaid D, Soliman E, Albenmoussa A, Bzeizi KI, Alabbad S, Alqahtani SA, Broering D, Al-Hamoudi W

- 282 Hospitalizations for alcoholic liver disease during the COVID-19 pandemic increased more for women, especially young women, compared to men

Campbell JP, Jahagirdar V, Muhanna A, Kennedy KF, Helzberg JH

- 289 Racial and gender-based disparities and trends in common psychiatric conditions in liver cirrhosis hospitalizations: A ten-year United States study

Patel P, Ali H, Inayat F, Pamarthy R, Giammarino A, Ilyas F, Smith-Martinez LA, Satapathy SK

Observational Study

- 303 Outcomes of gout in patients with cirrhosis: A national inpatient sample-based study

Khrais A, Kahlam A, Tahir A, Shaikh A, Ahlawat S

CASE REPORT

- 311 Autoimmune hepatitis and eosinophilia: A rare case report

Garrido I, Lopes S, Fonseca E, Carneiro F, Macedo G

LETTER TO THE EDITOR

- 318 Glecaprevir/pibrentasvir + sofosbuvir for post-liver transplant recurrent hepatitis C virus treatment

Arora R, Martin MT, Boike J, Patel S

ABOUT COVER

Editorial Board Member of *World Journal of Hepatology*, Hend M El Tayebi, PhD, Associate Professor, Pharmacist, Senior Scientist, Clinical Pharmacology and Pharmacogenomics Research Group, Department of Pharmacology and Toxicology, Faculty of Pharmacy and Biotechnology, German University in Cairo, Cairo 11835, Egypt. hend.saber@guc.edu.eg

AIMS AND SCOPE

The primary aim of *World Journal of Hepatology (WJH, World J Hepatol)* is to provide scholars and readers from various fields of hepatology with a platform to publish high-quality basic and clinical research articles and communicate their research findings online.

WJH mainly publishes articles reporting research results and findings obtained in the field of hepatology and covering a wide range of topics including chronic cholestatic liver diseases, cirrhosis and its complications, clinical alcoholic liver disease, drug induced liver disease autoimmune, fatty liver disease, genetic and pediatric liver diseases, hepatocellular carcinoma, hepatic stellate cells and fibrosis, liver immunology, liver regeneration, hepatic surgery, liver transplantation, biliary tract pathophysiology, non-invasive markers of liver fibrosis, viral hepatitis.

INDEXING/ABSTRACTING

The *WJH* is now abstracted and indexed in PubMed, PubMed Central, Emerging Sources Citation Index (Web of Science), Scopus, Reference Citation Analysis, China National Knowledge Infrastructure, China Science and Technology Journal Database, and Superstar Journals Database. The 2022 edition of Journal Citation Reports® cites the 2021 Journal Citation Indicator (JCI) for *WJH* as 0.52. The *WJH*'s CiteScore for 2021 is 3.6 and Scopus CiteScore rank 2021: Hepatology is 42/70.

RESPONSIBLE EDITORS FOR THIS ISSUE

Production Editor: *Yi-Xuan Cai*; Production Department Director: *Xiang Li*; Editorial Office Director: *Xiang Li*.

NAME OF JOURNAL

World Journal of Hepatology

ISSN

ISSN 1948-5182 (online)

LAUNCH DATE

October 31, 2009

FREQUENCY

Monthly

EDITORS-IN-CHIEF

Nikolaos Pylsopoulos, Ke-Qin Hu, Koo Jeong Kang

EDITORIAL BOARD MEMBERS

<https://www.wjgnet.com/1948-5182/editorialboard.htm>

PUBLICATION DATE

February 27, 2023

COPYRIGHT

© 2023 Baishideng Publishing Group Inc

INSTRUCTIONS TO AUTHORS

<https://www.wjgnet.com/bpg/gerinfo/204>

GUIDELINES FOR ETHICS DOCUMENTS

<https://www.wjgnet.com/bpg/GerInfo/287>

GUIDELINES FOR NON-NATIVE SPEAKERS OF ENGLISH

<https://www.wjgnet.com/bpg/gerinfo/240>

PUBLICATION ETHICS

<https://www.wjgnet.com/bpg/GerInfo/288>

PUBLICATION MISCONDUCT

<https://www.wjgnet.com/bpg/gerinfo/208>

ARTICLE PROCESSING CHARGE

<https://www.wjgnet.com/bpg/gerinfo/242>

STEPS FOR SUBMITTING MANUSCRIPTS

<https://www.wjgnet.com/bpg/GerInfo/239>

ONLINE SUBMISSION

<https://www.f6publishing.com>

Clostridioides difficile infection in patients with nonalcoholic fatty liver disease-current status

Yana V Kiseleva, Roman V Maslennikov, Aida N Gadzhiakhmedova, Tatyana S Zharikova, Dmitry V Kalinin, Yury O Zharikov

Specialty type: Gastroenterology and hepatology

Provenance and peer review: Invited article; Externally peer reviewed.

Peer-review model: Single blind

Peer-review report's scientific quality classification

Grade A (Excellent): 0
Grade B (Very good): B, B
Grade C (Good): 0
Grade D (Fair): D
Grade E (Poor): 0

P-Reviewer: He F, China; Zaiou M, France

Received: October 23, 2022

Peer-review started: October 23, 2022

First decision: December 12, 2022

Revised: December 26, 2022

Accepted: January 31, 2023

Article in press: January 31, 2023

Published online: February 27, 2023



Yana V Kiseleva, International School “Medicine of the Future”, I.M. Sechenov First Moscow State Medical University (Sechenov University), Moscow 119991, Russia

Roman V Maslennikov, Department of Internal Medicine, Gastroenterology and Hepatology, I.M. Sechenov First Moscow State Medical University (Sechenov University), Moscow 119435, Russia

Roman V Maslennikov, Department of Internal Medicine, Consultative and Diagnostic Center No. 2, Moscow City Health Department, Moscow 107564, Russia

Aida N Gadzhiakhmedova, Tatyana S Zharikova, Yury O Zharikov, Department of Human Anatomy and Histology, I.M. Sechenov First Moscow State Medical University (Sechenov University), Moscow 125009, Russia

Dmitry V Kalinin, Department of Pathology, A.V. Vishnevsky National Medical Research Center of Surgery, Moscow 115093, Russia

Corresponding author: Yury O Zharikov, MD, PhD, Associate Professor, Surgeon, Department of Human Anatomy and Histology, I.M. Sechenov First Moscow State Medical University (Sechenov University), Mokhovaya Street, 11s10, Moscow 125009, Russia.
dr_zharikov@mail.ru

Abstract

Nonalcoholic fatty liver disease (NAFLD) is the most common chronic liver disease, leading to fibrosis, cirrhosis and hepatocellular carcinoma and also associated with increased cardiovascular disease mortality. The pathogenesis of NAFLD is not fully understood, although NAFLD is thought to be a hepatic form of metabolic syndrome. There is an increasing understanding of the role of microbiota disturbances in NAFLD pathogenesis, and as with many other conditions affecting the microbiota, NAFLD may be a novel risk factor for *Clostridioides difficile* (*C. difficile*) colonization (CDC) and *C. difficile* infection (CDI). CDI is an emerging nosocomial disease, and community-acquired cases of infection are growing, probably due to an increase in CDC rates. The association of NAFLD with CDI has been shown in only 4 studies to date, three of which included less than 1000 patients, although the frequency of NAFLD in these studies was observed in almost 20% of the total patient cohort. These data revealed that NAFLD is a risk factor for CDI development and, moreover, is a risk factor for intestinal complications of CDI. More studies are needed to investigate this

association and move forward CDC and CDI screening efforts for this group of patients.

Key Words: Nonalcoholic fatty liver disease; *Clostridioides difficile*; *Clostridioides difficile* colonization; *Clostridioides difficile* infection; Minireview

©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.

Core Tip: The association of nonalcoholic fatty liver disease (NAFLD) with *Clostridioides difficile* (*C. difficile*) infection (CDI) has been shown in only 4 studies to date, three of which included less than 1000 patients, although the frequency of NAFLD in these studies was observed in almost 20% of the total patient cohort. These data revealed that NAFLD is a risk factor for CDI development and, moreover, is a risk factor for intestinal complications of CDI. More retr-ospetive studies and systematic reviews are needed to examine this group of patients as a risk factor for CDI, make recommendations to prevent CDI, and effectively screen and diagnose *C. difficile* colonization within NAFLD patients.

Citation: Kiseleva YV, Maslennikov RV, Gadzhiakhmedova AN, Zharikova TS, Kalinin DV, Zharikov YO. *Clostridioides difficile* infection in patients with nonalcoholic fatty liver disease-current status. *World J Hepatol* 2023; 15(2): 208-215

URL: <https://www.wjgnet.com/1948-5182/full/v15/i2/208.htm>

DOI: <https://dx.doi.org/10.4254/wjh.v15.i2.208>

INTRODUCTION

Nonalcoholic fatty liver disease (NAFLD) is characterized as a chronic liver disease with $\geq 5\%$ hepatic fat accumulation and a natural progressive course from nonalcoholic fatty liver (NFL) to nonalcoholic hepatitis (NASH) and cirrhosis. The current epidemiology of NAFLD is not totally understood due to its low diagnostic rates, as patients may remain asymptomatic even after the formation of cirrhosis and escape medical evaluation; however, NAFLD is thought to affect approximately 25% of the adult population, and the incidence of NAFLD is expected to increase in the future[1-3]. In NFL, the fibrosis progression rate averages 14 years *per* each stage of fibrosis *vs* 7 years *per* each stage of fibrosis in NASH. There are also rapid progressors with NASH in whom fibrosis progresses in less than 7 years. Among NAFLD patients, approximately 20% have NASH, and these patients should be diagnosed and receive proper treatment, as they can develop cirrhosis within 2-3 decades[4].

Patients with NAFLD are at risk for hepatocellular carcinoma (HCC), the fourth leading cause of cancer death worldwide, which may occur in the absence of cirrhosis in up to 50% of NAFLD patients, leading to late diagnosis and increased mortality[3,5,6]. In addition to cirrhosis and HCC, NAFLD is associated with an increased risk of cardiovascular disease (CVD), as these patients tend to have obesity, type 2 diabetes mellitus, and dyslipidemia, the hallmark of metabolic syndrome. Thus, these patients are at a higher risk for hypertension, coronary heart disease, cardiac arrhythmias, cardiomyopathy development and increased cardiovascular morbidity and mortality[7]. Nonobese patients with NAFLD have significantly lower rates of CVD than obese patients with NAFLD; however, even in the absence of obesity, patients with NAFLD are at a higher risk of CVD, with an incidence rate of 18.7 *per* 1000 persons-years[1]. In addition to the association of NAFLD with CVD and HCC, recent studies have shown that patients with NAFLD are at risk for *Clostridioides difficile* (*C. difficile*) infection (CDI) development[8-11].

ABOUT C. DIFFICILE

C. difficile is a gram-positive, spore-forming bacterium with transmission by the fecal-oral route. It is widespread in the environment and human population, may persist in the intestinal tract of asymptomatic carriers and animals and contaminate ambient objects, and can cause mild to severe diarrhea and colitis. In the last 30 years, CDI has become one of the most significant nosocomial infections and the leading cause of antibiotic-associated diarrhea, with increased severity, rate of recurrence (*i.e.*, up to 10%-30%) and mortality[12,13]. In 2011, 453000 new cases of CDI and 29300 associated deaths were identified in the United States; in 2017, the incidence was estimated at 223900 with 12800 deaths[14]. In Europe, the annual estimated number of cases is up to 189256, according to a 2016-2017 study[12]. The increased incidence and severity associated with CDI can be attributed to the emergence and spread of a strain known as ribotype 027 (NAP1/BI/027) among hospitalized patients

[15]. NAP1/BI/027 is highly resistant to fluoroquinolone, has increased toxin A and B production, produces a strain-specific binary toxin and persists in the United States and Europe; however, in Asia, the dominant strains include ribotype 017, 018 and 014[16]. Of note, drug resistance and severity of CDI also vary by ribotype and region. Developing diagnostic methods have led to an understanding of the heterogeneity of *C. difficile*, while molecular typing studies have demonstrated the presence of up to 98 different ribotypes in a single country[17,18].

C. difficile toxins cause acute colonic inflammation *via* epithelial disruption and the release of proinflammatory cytokines and chemokines, resulting in CDI, which is clinically heterogeneous. The severity of CDI is thought to be dependent on both the host and strain characteristics[17,19]. The distal colon is the most frequently affected organ in CDI, resulting in mild diarrhea with spontaneous recovery after antibiotic withdrawal. However, some patients manifest profuse diarrhea, colonic ileus, pseudomembranous colitis and toxic megacolon, followed by fever, abdominal pain, sepsis, *etc.* Clinical and laboratory findings may vary between patients depending on CDI severity including dehydration, peritonitis, leukocytosis, a positive fecal occult blood test, *etc.*; therefore, CDI should be suspected in any patient with acute diarrhea, recent antimicrobial exposure and a prolonged hospital stay[20,21]. Risk factors for CDI include non-CDI-active antimicrobial use, prolonged hospitalization, advanced age (≥ 65 years.) and recent intake of acid-suppressive therapy[20,22-24].

Recurrent CDI (rCDI) is a new CDI episode occurring within eight weeks after a previous episode. Etiologically, rCDI may be due to relapse of the same strain as the first infection or reinfection by a different strain, and it develops in 15% to 30% of patients after initial CDI. The risk of further recurrence is much higher, as approximately 40% of patients with one episode of rCDI will develop the second episode, whereas the third episode will develop in 45%-65% of patients. Thus, prevention of rCDI remains very important[25]. Risk factors for rCDI include advanced age (> 76 years), antibiotic exposure, gastric acid suppression, CDI caused by a highly virulent strain (NAP1/BI/027), severe underlying diseases and a prolonged hospital stay[25,26].

CDI diagnosis depends on clinical findings and the detection of *C. difficile*, its toxin or toxin-producing gene in a stool specimen taken before the initiation of *C. difficile*-specific treatment to avoid false-negative results. The European Society of Clinical Microbiology and Infectious Disease recommends a 2-step diagnostic algorithm for CDI confirmation. The first step is a highly sensitive screening method (*i.e.*, the nucleic acid amplification test and the glutamate dehydrogenase assay). Positive results are followed by the performance of a second step which includes detecting free toxins in stool (*i.e.*, the enzyme immunoassay for disease causing toxins or the cell cytotoxicity neutralization assay)[20,27].

Recently, there has been an interest in asymptomatic colonized individuals, acting as a reservoir for CDI and being at increased risk (*i.e.*, 51.9 cases *per* 100000 persons) of developing CDI[20]. *C. difficile* colonization (CDC) stands for the detection of *C. difficile* in the absence of CDI symptoms for 12 wk pre- or post-specimen collection; however, many studies use the simple definition of a *C. difficile*-positive stool and the absence of CDI symptoms[28]. *C. difficile* colonizes the gut of 5% of the adult population and up to 70% of infants and does not affect the intestinal tract while the gut microbiome is intact; however, administration of antibiotics affects its composition and promotes the growth of vegetative forms, the germination of spores, and the production of toxins[15,18]. Approximately 4%-10% of patients are colonized with *C. difficile* at the time of hospitalization, and the number of colonized patients increases during their stay[17]. Therefore, asymptomatic hospitalized patients require *C. difficile* screening to prevent microbe transmission and the development of strategies to mitigate the risks for developing active CDI[28,29].

C. DIFFICILE AND LIVER DISEASES

It is widely known that cirrhosis is associated with an increased risk of CDI and a severe disease course as cirrhotic patients have a high rate of hospitalization, an immunocompromised state, and are often prescribed to take antibiotics due to an increased risk of infection[30-32]. The average hospitalization stay in patients with CDI and cirrhosis is 14 d, inpatient mortality is $\geq 14\%$, and 30-d readmission rates occur in 35% of patients compared to the results for noncirrhotic patients, which are 13 d, 8% and 20%, respectively[33]. CDI is an independent mortality risk factor in cirrhotic patients as evident from the fact that mortality in a cohort of patients with cirrhosis and concurrent CDI were demonstrated to be higher (13.8%) than mortality in cirrhosis (8.2%) and CDI (9.6%) patients alone[34]. Moreover, hypoalbuminemia and admission to the intensive care unit are independent predictors for short-term mortality [35]. Sahra *et al*[36] revealed that patients with cirrhosis were more likely to develop CDI than noncirrhotic patients. Interestingly, the etiology of cirrhosis also affects CDI prevalence. For instance, patients with cirrhosis due to alcoholic liver disease (ALD) and NAFLD were more prone to CDI than patients with viral hepatitis B and C cirrhosis (174.0 *vs* 184.9, *vs* 81.7 *vs* 117.9 persons *per* 100000, respectively) [36].

In contrast to cirrhosis, the association between NAFLD and CDI is not fully understood. To the best of our knowledge, there are currently only four studies examining this question, even though NAFLD is

the most common cause of chronic liver disease and CDI is one of the most common nosocomial infections.

In November 2019, Nseir *et al*[9] published their retrospective cross-sectional study, revealing that NAFLD is a risk factor for *C. difficile*-associated diarrhea (CDAD). Patients with NAFLD accounted for 66% of all patients with confirmed CDAD. Moreover, the authors revealed that metabolic syndrome, which is commonly seen in patients with NAFLD, is associated with severe CDAD[9]. A similar retrospective study by Papić *et al*[8] confirmed that NAFLD is a risk factor for inpatient CDI, with an incidence rate of 16.9% *vs* 7.4%, as seen in the control group.

In 2021, Jiang *et al*[10] presented a large retrospective study that included 7239 patients with CDI and coexisting NAFLD (with a total of 94.5% that were noncirrhotic) and compared them to patients with coexisting ALD and viral liver disease (VLD). The analysis showed that patients in the NAFLD group had a lower incidence of respiratory failure (2.7%), septic shock (0.5%), acute kidney injury (13%), hospital mortality (0.8%) and length of stay (5.75 ± 0.16 d) than those in the ALD and VLD groups; however, the rates for intestinal complications were increased in the NAFLD group. Specifically, intestinal obstruction was seen in 4.6% of patients with NAFLD compared to 2.2% of patients with ALD. Additionally, a higher rate of intestinal perforation was observed in the NAFLD group compared to the VLD group[10].

Recently, Šamadan *et al*[11] revealed that NAFLD is not only a risk factor for inpatient CDI in elderly patients exposed to systemic antibiotics but also a risk factor for rCDI (47.4% in the NAFLD group compared to 27.9% in the non-NAFLD group). Interestingly, the authors found a decreased rCDI ratio in patients taking statins in both the NAFLD and non-NAFLD groups, possibly due to their modulatory effect on the microbiome[11].

GUT MICROBIOTA DISTURBANCES IN NAFLD AND CDI PATHOGENESIS

Although the association of NAFLD with CDI has not been fully studied, biological plausible links may lie in their shared pathogenesis (*i.e.*, the gut microbiota disturbances).

It is widely accepted that microbiota disturbances play a main role in *C. difficile* colonization and infection; therefore, it is not surprising that most patients develop CDI after a course of antibiotics. The pathogenesis of *C. difficile* colonization and infection includes intermicrobial interactions. For instance, *C. difficile* produces quorum signals, inducing Proteobacteria metabolite production leading to Bacteroidetes inhibition. *C. difficile* can also produce inhibitors of indigenous microbiota, such as proline-base cyclic dipeptides[37]. Secondary bile acids have been shown to inhibit toxin activity and the growth of vegetative forms of *C. difficile*, while antibiotics affect microbes producing these acids. In contrast, primary bile acids promote *C. difficile* spore germination. Therefore, a low level of secondary bile salts (and consequently a low concentration of secondary bile acid-producing bacteria) and a high level of primary bile salts, results in CDI and its recurrence[38].

Multiple studies have shown that smaller microbial diversity and decreases in certain species are often seen in patients with CDI and CDC. For example, stool samples of patients with CDI revealed an increase in Proteobacteria, Firmicutes and Enterobacteriales, and a decrease in Bacteroidetes and butyrate-producing Ruminococcaceae and Lachnospiraceae families in comparison to healthy individuals[28].

The CDC microbiome disturbances were similar to those of CDI patients; however, in regard to the degree of changes seen, they were closer to healthy individuals. In addition, a higher level of some bacterial families were noted in CDC microbiomes, including Clostridiales family XI incertae sedis, Clostridium, and Eubacterium, but were significantly decreased in the infected individuals[39]. This data confirms that CDI occurrence is dependent on the presence of certain bacterial species and that colonization with these species may prevent CDC and CDI[40]. Studies on murine models have already confirmed that intestinal colonization with Lachnospiraceae significantly reduced CDC and that administration of *Clostridium scindens* prevented CDI development in antibiotic treated mice with *C. difficile* spores[41,42]. From these studies it can be inferred that any condition connected with gut microbiota disturbance is a risk factor for CDC and CDI.

Recently, there has been increasing evidence of the role of microbiota disturbances in NAFLD pathogenesis and progression[43-45]. For example, it was shown that the transfer of the microbiome from mice with fasting hyperglycemia and insulinemia to germ-free mice led to the development of NAFLD. These conventionalized NAFLD mice had Lachnospiraceae bacterium 609 and *Barnesiella intestihominis* overrepresented in their feces, whereas *Bacteroides vulgatus* (*B. vulgatus*) was underrepresented in comparison to the control group[46].

Changes in the gut microbiota were also found in humans with NAFLD. Moreover, the composition of the gut microbiota varied not only between the control group and patients with NAFLD but also between patients with NAFLD, NASH and NAFLD cirrhosis[47]. Loomba *et al*[48] revealed the dominance of Firmicutes and Bacteroidetes in NAFLD patients; however, the progression of the disease from mild/moderate to advanced fibrosis led to an increase in Proteobacteria and a decrease in Firmicutes. *Eubacterium rectale* and *B. vulgatus* were shown to be the most abundant species in mild/

Table 1 Nonalcoholic fatty liver disease association with *Clostridioides difficile* infection and recurrent *Clostridioides difficile* infection

Ref.	Year of publication	Type of publication	Number of patients	Correlation between NAFLD/CDI
Nseir <i>et al</i> [9]	2020	Retrospective study	115	NAFLD was found in 76/115 (66%) patients with CDAD vs 35/115 (30.4%) in the control group, $P < 0.001$ Multivariate analysis showed that NAFLD was significantly associated with CDAD (OR: 1.51, 95%CI: $P = 0.05$)
Papić <i>et al</i> [8]	2020	Retrospective cohort study	314	CDI was significantly more frequent in patients with NAFLD (14, 16.87% vs 17, 7.36%, $P = 0.0156$)
Šamadan <i>et al</i> [11]	2021	Retrospective cohort study	329	Multivariable Cox regression analysis showed that age > 75 yr, NAFLD, CACI > 6, chronic kidney disease, statins and immobility were associated with rCDI
Jiang <i>et al</i> [10]	2021	Retrospective cohort study	7239	CDI with NAFLD was associated with a higher rate of intestinal perforation ($P < 0.01$) when compared to viral liver disease and a higher rate of intestinal obstruction (4.6% vs 2.2%, $P = 0.001$) when compared to CDI with ALD

NAFLD: Nonalcoholic fatty liver disease; CDI: *Clostridioides difficile* infection; ALD: Alcoholic liver disease; CDAD: *Clostridioides difficile*-associated diarrhea; rCDI: Recurrent *Clostridioides difficile* infection.

moderate NAFLD, and *B. vulgatus* (2.2%) and *Escherichia coli* were the most abundant in advanced fibrosis, suggesting a shift toward gram-negative microbes in which lipopolysaccharide is thought to cause the progression of fibrosis. Proteobacteria, Enterobacteria, *Escherichia* and *Bacteroides* were found in abundance in patients with NASH, while Gammaproteobacteria and *Prevotella* were more prevalent in the stool of obese children with NAFLD in comparison to non-NAFLD obese children [46, 49]. Zhu *et al* [50] found an increased representation of an alcohol-producing *Escherichia*, followed by increased blood alcohol concentration, in NASH patients compared to obese and healthy individuals, which may play a role in NASH pathogenesis. Zhang *et al* [51] showed the association of a high-fat/high-cholesterol diet with progression of NAFLD and the concomitant changes in the microbiota of mice. Thus, enrichment of *Mucispirillum schaedleri*_Otu038, *Desulfovibrio*_Otu047, *Anaerotruncus*_Otu107, *Desulfovibrionaceae*_Otu073, *Clostridium celatum*_Otu070, *C. ruminantium*_Otu059, *C. cocelatum*_Otu036 and *C. methylpentosum*_Otu053, and the depletion of *Bifidobacterium*_Otu026, *Akkermansia municipihila*_Otu034, *Lactobacillus*_Otu009, *Bacteroides acidifaciens*_Otu032, *Bacteroides*_Otu012, *B. uniformis*_Otu080 and *B. eggerthii*_Otu079 in the microbiota were observed with the progression of NAFLD to NASH and HAFLD-HCC. The authors also revealed a possible role of *Helicobacter ganmanii*_Otu031 enrichment and *Bacteroides*_Otu012 depletion in HCC development in mice. Lastly, fecal microbiome transplantation from NAFLD patients to germ-free mice confirmed a role of gut microbiota in NAFLD pathogenesis as these mice showed hepatic steatosis, inflammation and multifocal necrosis on a high-fat diet (HFD), while germ-free mice from the control group only had minor liver inflammation and fat accumulation on the same HFD [52]. Therefore, the gut microbiota disturbances seen in both NAFLD and CDC/CDI and preexisting microbiota changes in patients with NAFLD may explain its association with CDI and rCDI [8-10].

CONCLUSION

NAFLD is the most common chronic liver disease with an estimated prevalence of 20% in the general population. NAFLD is a well-known risk factor for cirrhosis and HCC development and is also associated with cardiovascular mortality. Although the pathogenesis of NAFLD is not fully understood, the past decade of research has led to an understanding of the role of the gut microbiota in NAFLD development and progression toward cirrhosis. As with any condition associated with microbiota disturbance, NAFLD has been shown to be associated with CDI severity. Despite NAFLD being such a common, chronic liver disease and *C. difficile* being an emerging nosocomial infection with increasing community-acquired cases, only 4 studies have examined this issue, to date (Table 1). More retrospective studies and systematic reviews are needed to examine this group of patients as a risk factor for CDI, make recommendations to prevent CDI, and effectively screen and diagnose CDC within NAFLD patients.

FOOTNOTES

Author contributions: Kiseleva YV is responsible for conceptualization, supervision, manuscript first draft preparation, approved final draft; Maslennikov RV is responsible for supervision, data acquisition, approved final

draft; Gadzhiakhmedova AN is responsible for data acquisition, visualization, manuscript writing and editing, approved final draft; Zharikova TS is responsible for data acquisition, formal analysis, manuscript writing and editing, approved final draft; Kalinin DV is responsible for visualization, formal analysis, manuscript writing, review and editing, approved final draft; Zharikov YO is responsible for supervision, conceptualization, manuscript first draft preparation, review and editing, approved final draft.

Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.

Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <https://creativecommons.org/licenses/by-nc/4.0/>

Country/Territory of origin: Russia

ORCID number: Yana V Kiseleva 0000-0002-0009-9245; Roman V Maslennikov 0000-0001-7513-1636; Aida N Gadzhiakhmedova 0000-0003-2557-5647; Tatyana S Zharikova 0000-0001-6842-1520; Dmitry V Kalinin 0000-0001-6247-9481; Yuri O Zharikov 0000-0001-9636-3807.

S-Editor: Fan JR

L-Editor: A

P-Editor: Fan JR

REFERENCES

- 1 **Pafili K**, Roden M. Nonalcoholic fatty liver disease (NAFLD) from pathogenesis to treatment concepts in humans. *Mol Metab* 2021; **50**: 101122 [PMID: 33220492 DOI: 10.1016/j.molmet.2020.101122]
- 2 **Younossi Z**, Tacke F, Arrese M, Chander Sharma B, Mostafa I, Bugianesi E, Wai-Sun Wong V, Yilmaz Y, George J, Fan J, Vos MB. Global Perspectives on Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis. *Hepatology* 2019; **69**: 2672-2682 [PMID: 30179269 DOI: 10.1002/hep.30251]
- 3 **Huang DQ**, El-Serag HB, Loomba R. Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention. *Nat Rev Gastroenterol Hepatol* 2021; **18**: 223-238 [PMID: 33349658 DOI: 10.1038/s41575-020-00381-6]
- 4 **Loomba R**, Friedman SL, Shulman GI. Mechanisms and disease consequences of nonalcoholic fatty liver disease. *Cell* 2021; **184**: 2537-2564 [PMID: 33989548 DOI: 10.1016/j.cell.2021.04.015]
- 5 **Foerster F**, Gairing SJ, Müller L, Galle PR. NAFLD-driven HCC: Safety and efficacy of current and emerging treatment options. *J Hepatol* 2022; **76**: 446-457 [PMID: 34555422 DOI: 10.1016/j.jhep.2021.09.007]
- 6 **Mundi MS**, Velapati S, Patel J, Kellogg TA, Abu Dayyeh BK, Hurt RT. Evolution of NAFLD and Its Management. *Nutr Clin Pract* 2020; **35**: 72-84 [PMID: 31840865 DOI: 10.1002/ncp.10449]
- 7 **Kasper P**, Martin A, Lang S, Kütting F, Goeser T, Demir M, Steffen HM. NAFLD and cardiovascular diseases: a clinical review. *Clin Res Cardiol* 2021; **110**: 921-937 [PMID: 32696080 DOI: 10.1007/s00392-020-01709-7]
- 8 **Papić N**, Jelovčić F, Karlović M, Marić LS, Vince A. Nonalcoholic fatty liver disease as a risk factor for *Clostridioides difficile* infection. *Eur J Clin Microbiol Infect Dis* 2020; **39**: 569-574 [PMID: 31782025 DOI: 10.1007/s10096-019-03759-w]
- 9 **Nseir WB**, Hussein SHH, Farah R, Mahamid MN, Khatib HH, Mograbi JM, Peretz A, Amara AE. Nonalcoholic fatty liver disease as a risk factor for *Clostridium difficile*-associated diarrhea. *QJM* 2020; **113**: 320-323 [PMID: 31688897 DOI: 10.1093/qjmed/hec283]
- 10 **Jiang Y**, Chowdhury S, Xu BH, Meybodi MA, Damiris K, Devalaraju S, Pyrsopoulos N. Nonalcoholic fatty liver disease is associated with worse intestinal complications in patients hospitalized for *Clostridioides difficile* infection. *World J Hepatol* 2021; **13**: 1777-1790 [PMID: 34904045 DOI: 10.4254/wjh.v13.i11.1777]
- 11 **Šamadan L**, Jeličić M, Vince A, Papić N. Nonalcoholic Fatty Liver Disease-A Novel Risk Factor for Recurrent *Clostridioides difficile* Infection. *Antibiotics (Basel)* 2021; **10** [PMID: 34198964 DOI: 10.3390/antibiotics10070780]
- 12 **Kampouri E**, Croxatto A, Prod'hom G, Guery B. *Clostridioides difficile* Infection, Still a Long Way to Go. *J Clin Med* 2021; **10** [PMID: 33498428 DOI: 10.3390/jcm10030389]
- 13 **O'Grady K**, Knight DR, Riley TV. Antimicrobial resistance in *Clostridioides difficile*. *Eur J Clin Microbiol Infect Dis* 2021; **40**: 2459-2478 [PMID: 34427801 DOI: 10.1007/s10096-021-04311-5]
- 14 **Centers for Disease Control and Prevention (U.S.)**. Antibiotic Resistance Threats in the United States, 2019. Georgia, US: Centers for Disease Control and Prevention (U.S.), 2019
- 15 **Czepiel J**, Drózdź M, Pituch H, Kuijper EJ, Perucki W, Mielimonka A, Goldman S, Wultańska D, Garlicki A, Biesiada G. *Clostridium difficile* infection: review. *Eur J Clin Microbiol Infect Dis* 2019; **38**: 1211-1221 [PMID: 30945014 DOI: 10.1007/s10096-019-03539-6]
- 16 **Guh AY**, Kutty PK. *Clostridioides difficile* Infection. *Ann Intern Med* 2018; **169**: ITC49-ITC64 [PMID: 30285209 DOI: 10.7326/AITC201810020]
- 17 **Martin JS**, Monaghan TM, Wilcox MH. *Clostridium difficile* infection: epidemiology, diagnosis and understanding transmission. *Nat Rev Gastroenterol Hepatol* 2016; **13**: 206-216 [PMID: 26956066 DOI: 10.1038/nrgastro.2016.25]
- 18 **Martínez-Meléndez A**, Morfin-Otero R, Villarreal-Treviño L, Baines SD, Camacho-Ortiz A, Garza-González E. Molecular epidemiology of predominant and emerging *Clostridioides difficile* ribotypes. *J Microbiol Methods* 2020; **175**:

- 105974 [PMID: 32531232 DOI: 10.1016/j.mimet.2020.105974]
- 19 **Chandrasekaran R**, Lacy DB. The role of toxins in Clostridium difficile infection. *FEMS Microbiol Rev* 2017; **41**: 723-750 [PMID: 29048477 DOI: 10.1093/femsre/flux048]
 - 20 **Abad CLR**, Safdar N. A Review of Clostridioides difficile Infection and Antibiotic-Associated Diarrhea. *Gastroenterol Clin North Am* 2021; **50**: 323-340 [PMID: 34024444 DOI: 10.1016/j.gtc.2021.02.010]
 - 21 **Mounsey A**, Lacy Smith K, Reddy VC, Nickolich S. Clostridioides difficile Infection: Update on Management. *Am Fam Physician* 2020; **101**: 168-175 [PMID: 32003951]
 - 22 **Wagner JL**, Stover KR, Bell AM, Barber KE. Risk factors for development of initial Clostridioides difficile infection. *J Glob Antimicrob Resist* 2021; **25**: 18-22 [PMID: 33667706 DOI: 10.1016/j.jgar.2021.02.012]
 - 23 **Honda H**, Kato H, Olsen MA, Reske KA, Senoh M, Fukuda T, Tagashira Y, Mahe C, Dubberke ER; Clostridioides difficile infection Japan study group. Risk factors for Clostridioides difficile infection in hospitalized patients and associated mortality in Japan: a multi-centre prospective cohort study. *J Hosp Infect* 2020; **104**: 350-357 [PMID: 31542458 DOI: 10.1016/j.jhin.2019.09.012]
 - 24 **Anjewierden S**, Han Z, Brown AM, Donskey CJ, Deshpande A. Risk factors for Clostridioides difficile colonization among hospitalized adults: A meta-analysis and systematic review. *Infect Control Hosp Epidemiol* 2021; **42**: 565-572 [PMID: 33118886 DOI: 10.1017/ice.2020.1236]
 - 25 **Song JH**, Kim YS. Recurrent Clostridium difficile Infection: Risk Factors, Treatment, and Prevention. *Gut Liver* 2019; **13**: 16-24 [PMID: 30400734 DOI: 10.5009/gnl18071]
 - 26 **Alrahmany D**, Ereshefsky BJ, El Nekidy WS, Harb G, Pontiggia L, Ghazi IM. Risk Factors for Recurrence of Clostridioides difficile in Hospitalized Patients. *J Infect Public Health* 2021; **14**: 1642-1649 [PMID: 34627059 DOI: 10.1016/j.jiph.2021.09.016]
 - 27 **Del Prete R**, Ronga L, Addati G, Magrone R, Abbasciano A, Decimo M, Miragliotta G. Clostridium difficile. A review on an emerging infection. *Clin Ter* 2019; **170**: e41-e47 [PMID: 30789196 DOI: 10.7417/CT.2019.2106]
 - 28 **Crobach MJT**, Vernon JJ, Loo VG, Kong LY, Péchiné S, Wilcox MH, Kuijper EJ. Understanding Clostridium difficile Colonization. *Clin Microbiol Rev* 2018; **31** [PMID: 29540433 DOI: 10.1128/CMR.00021-17]
 - 29 **Cui Y**, Dong D, Zhang L, Wang D, Jiang C, Ni Q, Wang C, Mao E, Peng Y. Risk factors for Clostridioides difficile infection and colonization among patients admitted to an intensive care unit in Shanghai, China. *BMC Infect Dis* 2019; **19**: 961 [PMID: 31711425 DOI: 10.1186/s12879-019-4603-1]
 - 30 **Kim D**, Yoo ER, Li AA, Tighe SP, Cholankeril G, Ahmed A. Trends in Hospitalizations for Clostridioides difficile Infection in End-Stage Liver Disease, 2005-2014. *Dig Dis Sci* 2021; **66**: 296-307 [PMID: 32124196 DOI: 10.1007/s10620-020-06162-0]
 - 31 **Cheng YW**, Alhaffar D, Saha S, Khanna S, Bohm M, Phelps E, Ghabril M, Orman E, Sashidhar S, Rogers N, Xu H, Khoruts A, Vaughn B, Kao D, Wong K, Cammarota G, Ianiro G, Dhare T, Kraft CS, Mehta N, Woodworth MH, Allegretti JR, Nativ L, Marcus J, El-Nachef N, Fischer M. Fecal Microbiota Transplantation Is Safe and Effective in Patients With Clostridioides difficile Infection and Cirrhosis. *Clin Gastroenterol Hepatol* 2021; **19**: 1627-1634 [PMID: 32645451 DOI: 10.1016/j.cgh.2020.06.051]
 - 32 **Trifan A**, Stoica O, Stanciu C, Cojocariu C, Singeap AM, Girleanu I, Miftode E. Clostridium difficile infection in patients with liver disease: a review. *Eur J Clin Microbiol Infect Dis* 2015; **34**: 2313-2324 [PMID: 26440041 DOI: 10.1007/s10096-015-2501-z]
 - 33 **Phatharacharukul P**, Purpura RD, Gandhi D, Xu H, Bickett-Burkhart K, Chalasani N, Fischer M, Orman ES. Incidence and Risk Factors of Recurrent Clostridioides difficile Infection in Patients With Cirrhosis. *Clin Transl Gastroenterol* 2020; **11**: e00189 [PMID: 32675703 DOI: 10.14309/ctg.0000000000000189]
 - 34 **Abdalla AO**, Pisipati S, Elnaggar M, Rishi M, Doshi R, Gullapalli N. Outcomes of Clostridioides difficile Infection in Patients With Liver Cirrhosis: A Nationwide Study. *Gastroenterology Res* 2020; **13**: 53-57 [PMID: 32362963 DOI: 10.14740/gr1240]
 - 35 **Liu Y**, Chen M. Clostridioides difficile Infection in Liver Cirrhosis: A Concise Review. *Can J Gastroenterol Hepatol* 2022; **2022**: 4209442 [PMID: 35711246 DOI: 10.1155/2022/4209442]
 - 36 **Sahra S**, Abureesh M, Amarnath S, Alkhayyat M, Badran R, Jahangir A, Gumaste V. Clostridioides difficile infection in liver cirrhosis patients: A population-based study in United States. *World J Hepatol* 2021; **13**: 926-938 [PMID: 34552699 DOI: 10.4254/wjh.v13.i8.926]
 - 37 **Khoruts A**, Staley C, Sadowsky MJ. Faecal microbiota transplantation for Clostridioides difficile: mechanisms and pharmacology. *Nat Rev Gastroenterol Hepatol* 2021; **18**: 67-80 [PMID: 32843743 DOI: 10.1038/s41575-020-0350-4]
 - 38 **Sehgal K**, Khanna S. Gut microbiome and Clostridioides difficile infection: a closer look at the microscopic interface. *Therap Adv Gastroenterol* 2021; **14**: 1756284821994736 [PMID: 33747125 DOI: 10.1177/1756284821994736]
 - 39 **Zhang L**, Dong D, Jiang C, Li Z, Wang X, Peng Y. Insight into alteration of gut microbiota in Clostridium difficile infection and asymptomatic C. difficile colonization. *Anaerobe* 2015; **34**: 1-7 [PMID: 25817005 DOI: 10.1016/j.anaerobe.2015.03.008]
 - 40 **Vincent C**, Miller MA, Edens TJ, Mehrotra S, Dewar K, Manges AR. Bloom and bust: intestinal microbiota dynamics in response to hospital exposures and Clostridium difficile colonization or infection. *Microbiome* 2016; **4**: 12 [PMID: 26975510 DOI: 10.1186/s40168-016-0156-3]
 - 41 **Buffie CG**, Bucci V, Stein RR, McKenney PT, Ling L, Gobourne A, No D, Liu H, Kinnebrew M, Viale A, Littmann E, van den Brink MR, Jenq RR, Taur Y, Sander C, Cross JR, Toussaint NC, Xavier JB, Pamer EG. Precision microbiome reconstitution restores bile acid mediated resistance to Clostridium difficile. *Nature* 2015; **517**: 205-208 [PMID: 25337874 DOI: 10.1038/nature13828]
 - 42 **Reeves AE**, Koenigsknecht MJ, Bergin IL, Young VB. Suppression of Clostridium difficile in the gastrointestinal tracts of germfree mice inoculated with a murine isolate from the family Lachnospiraceae. *Infect Immun* 2012; **80**: 3786-3794 [PMID: 22890996 DOI: 10.1128/IAI.00647-12]
 - 43 **Wu L**, Li J, Feng J, Ji J, Yu Q, Li Y, Zheng Y, Dai W, Wu J, Guo C. Crosstalk between PPARs and gut microbiota in NAFLD. *Biomed Pharmacother* 2021; **136**: 111255 [PMID: 33485064 DOI: 10.1016/j.biopha.2021.111255]

- 44 **Ji Y**, Yin Y, Li Z, Zhang W. Gut Microbiota-Derived Components and Metabolites in the Progression of Non-Alcoholic Fatty Liver Disease (NAFLD). *Nutrients* 2019; **11** [PMID: 31349604 DOI: 10.3390/nu11081712]
- 45 **Safari Z**, Gérard P. The links between the gut microbiome and non-alcoholic fatty liver disease (NAFLD). *Cell Mol Life Sci* 2019; **76**: 1541-1558 [PMID: 30683985 DOI: 10.1007/s00018-019-03011-w]
- 46 **Kolodziejczyk AA**, Zheng D, Shibolet O, Elinav E. The role of the microbiome in NAFLD and NASH. *EMBO Mol Med* 2019; **11** [PMID: 30591521 DOI: 10.15252/emmm.201809302]
- 47 **Aron-Wisnewsky J**, Vigliotti C, Witjes J, Le P, Holleboom AG, Verheij J, Nieuwdorp M, Clément K. Gut microbiota and human NAFLD: disentangling microbial signatures from metabolic disorders. *Nat Rev Gastroenterol Hepatol* 2020; **17**: 279-297 [PMID: 32152478 DOI: 10.1038/s41575-020-0269-9]
- 48 **Loomba R**, Seguritan V, Li W, Long T, Klitgord N, Bhatt A, Dulai PS, Caussy C, Bettencourt R, Highlander SK, Jones MB, Sirlin CB, Schnabl B, Brinkac L, Schork N, Chen CH, Brenner DA, Biggs W, Yooseph S, Venter JC, Nelson KE. Gut Microbiome-Based Metagenomic Signature for Non-invasive Detection of Advanced Fibrosis in Human Nonalcoholic Fatty Liver Disease. *Cell Metab* 2017; **25**: 1054-1062.e5 [PMID: 28467925 DOI: 10.1016/j.cmet.2017.04.001]
- 49 **Pérez-Montes de Oca A**, Julián MT, Ramos A, Puig-Domingo M, Alonso N. Microbiota, Fiber, and NAFLD: Is There Any Connection? *Nutrients* 2020; **12** [PMID: 33053631 DOI: 10.3390/nu12103100]
- 50 **Zhu L**, Baker SS, Gill C, Liu W, Alkhouri R, Baker RD, Gill SR. Characterization of gut microbiomes in nonalcoholic steatohepatitis (NASH) patients: a connection between endogenous alcohol and NASH. *Hepatology* 2013; **57**: 601-609 [PMID: 23055155 DOI: 10.1002/hep.26093]
- 51 **Zhang X**, Coker OO, Chu ES, Fu K, Lau HCH, Wang YX, Chan AWH, Wei H, Yang X, Sung JJY, Yu J. Dietary cholesterol drives fatty liver-associated liver cancer by modulating gut microbiota and metabolites. *Gut* 2021; **70**: 761-774 [PMID: 32694178 DOI: 10.1136/gutjnl-2019-319664]
- 52 **Chiu CC**, Ching YH, Li YP, Liu JY, Huang YT, Huang YW, Yang SS, Huang WC, Chuang HL. Nonalcoholic Fatty Liver Disease Is Exacerbated in High-Fat Diet-Fed Gnotobiotic Mice by Colonization with the Gut Microbiota from Patients with Nonalcoholic Steatohepatitis. *Nutrients* 2017; **9** [PMID: 29113135 DOI: 10.3390/nu9111220]



Published by **Baishideng Publishing Group Inc**
7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Telephone: +1-925-3991568

E-mail: bpgoffice@wjgnet.com

Help Desk: <https://www.f6publishing.com/helpdesk>

<https://www.wjgnet.com>

